PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom ...
Healio

Oral GLP-1 reduces body weight, HbA1c for adults with obesity plus type 2 diabetes

A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic parameters for adults with obesity and type 2 diabetes, according to findings from ...
Managed Healthcare Executive

FDA approves Poherdy, first biosimilar of Perjeta, to treat HER-positive breast cancer

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

From too much hunger to pimples: 5 common signs of worms that adults often ignore

Worm infections are generally thought of as a childhood problem. The truth, however, is that adults too carry a risk, ...
The Manila Times

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1 ...

Kura Oncology will host a conference call on November 13, 2025, at 12:30 pm ET / 9:30 am PT -SAN DIEGO and TOYKO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: ...

FDA approves Linzess (Linaclotide) for kids 7+ with IBS-C: First-ever treatment for pediatric constipation pain

The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...
The Manila Times

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® ...
Managed Healthcare Executive

Tyruko, the first biosimilar to treat multiple sclerosis, is now available

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...
The American Journal of Managed Care

High Fiber Linked to Fewer Bowel Symptoms in CRC Survivors

CRC survivors experience higher rates of long-term bowel dysfunction compared to non-CRC individuals, with symptoms persisting up to five years post-diagnosis. Increased dietary fiber intake is linked ...
Business Insider

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in ...

STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from ...

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...
GEN - Genetic Engineering and Biotechnology News

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.